Clinical Trial Update: Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tocilizumab with an 8-week prednisone taper versus 26 weeks of prednisone in giant cell arteritis; trial not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Arteritis

Drugs mentioned

• Actemra (tocilizumab) (tocilizumab)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Giant Cell Arteritis (GCA) | Phase 3 | Status: NOT_YET_RECRUITING